靛玉红-3'-单肟 - CAS:160807-49-8 - CAS号查询_生物试剂_化学试剂_分析试剂

中文名称:	靛玉红-3'-单肟促销
英文名称:	Indirubin-3′-oxime
别名:	靛玉红-3'-单肟 Indirubin-3′-monoxime
CAS No:	160807-49-8	分子式:	C₁₆H₁₁N₃O₂	分子量:	277.28
CAS No:	160807-49-8
分子式:	C₁₆H₁₁N₃O₂
分子量:	277.28

安全技术说明书(PDF) MSDS(PDF) 点击下载技术规格说明书(PDF) 点击下载产品说明书(PDF)

I10372 靛玉红-3'-单肟 ≥98% (psaitong)

相关产品

GSK-3β inhibitor 12
CAS No：784170-07-6
TWS 119
CAS No：1507095-58-0
GSK-3抑制剂II
CAS No：478482-75-6
KY19382
CAS No：2226664-93-1
1-(7-甲氧基喹啉-4-基)-3-[6-(三氟甲基)吡啶-2-基]脲
CAS No：1384424-80-9
WAY-313201
CAS No：571904-77-3

包装规格：

5mg 25mg 100mg in glass bottle

溶解性：

溶于DMSO(＞10mg/ml）

产品描述：

基本信息

产品编号：	I10372
产品名称：	Indirubin-3′-oxime
CAS:	160807-49-8	储存条件	粉末	-20℃	四年

分子式：	C16H11N3O2		溶于液体	-80℃	6个月
分子量：	277.28			-20℃	1个月
化学名：	3-[(3E)-3-(HYDROXYIMINO)-2,3-DIHYDRO-1H-INDOL-2-YLIDENE]-2,3-DIHYDRO-1H-INDOL-2-ONE
Solubility (25°C)：
体外:	DMSO	55mg/mL (198.35mM)
	Ethanol	Insoluble
	Water	Insoluble
体内(现配现用):	1.请依序添加每种溶剂：10% DMSO→40% PEG300→5% Tween-80→45% saline Solubility:≥2.5mg/mL(9.02mM);Clear solution
	此方案可获得 ≥ 2.5 mg/mL (9.02 mM，饱和度未知) 的澄清溶液。以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
＜1mg/ml表示微溶或不溶。
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

制备储备液

浓度溶液体积质量	1mg	5mg	10mg
1mM	3.6065mL	18.0323mL	36.0646mL
5mM	0.7213mL	3.6065mL	7.2129mL
10mM	0.3606mL	1.8032mL	3.6065mL

生物活性

产品描述	一种有效的GSK-3β抑制剂
靶点	GSK-3β 22nM (IC50)	CDK5/p25 100nM (IC50)	CDK1/cyclin B 180nM (IC50)	5-LOX 7.8-10μM (IC50)
体外研究	Indirubin-3'-monoxime inhibits GSK-3βby competing with ATP,with Ki of 0.85μM,and Km of 110μM.Indirubin-3'-monoxime also inhibits tau phosphorylation by GSK-3β,with an IC50 value of around 100nM.Indirubin-3'-monoxime completely inhibits the phosphorylation of the AT100 epitope.Indirubin-3'-monoxime inhibits vascular smooth muscle cell (VSMC) proliferation with IC50 of -2µM.Indirubin-3'-monoxime blunts migration of VSMC stimulated with the PDGF.Indirubin-3'- monoxime interferes with the migratory response in VSMC,and also suppresses the production of pro-migratory LT in monocytes.Moreover,Indirubin-3'-monoxime inhibits 5-lipoxygenase (5-LO) product synthesis in monocytes and neutrophils, with the same potency (IC50=5.0±1.1 and 3.7±1.2µM,respectively). Indirubin-3'-monoxime is an inhibitor of 5- LO,with IC50 of 7.8-10µM in cell-free assay.
体内研究	Indirubin-3'-monoxime (0.1,0.2 and 0.4mg/kg,i.p) dose dependently reverses the cognitive impairment and combats the elevated oxidative stress markers in HFD fed mice. Indirubin-3'-monoxime also dose dependently lowers the serum glucose,TGs,TC and insulin levels, and improves the β-cell functioning in HFD fed mice.Moreover,Indirubin-3'-monoxime treatment significantly decreases HOMA-IR levels compared to HFD group.Indirubin-3'-monoxime (0.4mg/kg) significantly attenuates the increased EL in the HFD group.

推荐实验方法(仅供参考)

激酶实验：

GSK-3βis expressed in and purified from insect Sf9 cells.It is assayed,following a 1/100 dilution in 1mg/mL BSA,10mM DTT,with 5μL of 40μM GS-1 peptide as a substrate,in buffer A,in the presence of 15μM[γ-32P]ATP (3000 Ci/mmol;1 mCi/mL) in a final volume of 30μL.After 30-min incubation at 30℃,25-μL aliquots of supernatant are spotted onto 2.5×3-cm pieces of Whatman P81 phosphocellulose paper,and,20 s later,the filters are washed five times (for at least 5 min each time) in a solution of 10mL of phosphoric acid/liter of water.The wet filters are counted in the presence of 1mL of ACS scintillation fluid.

细胞实验:

Cytotoxicity of Indirubin-3'-monoxime in monocytes is analysed by MTT assay in a 96-well format using a multi-well scanning spectrophotometer. Neutrophils (5×106 cells/mL) or monocytes (2×106 cells/mL) are incubated for 30 min with Indirubin-3'-monoxime,and the viability of the cells is analysed by MTT assay.Compared with vehicle (0.3% DMSO),no significant acute cytotoxicity is observed (neutrophils:103.9±4.4%;monocytes: 129.4±5.4%;n=3,each).

动物实验:

Male mice (5-6 weeks old) are randomLy assigned into five groups (n=10).Group 1:receive normal pellet diet (NPD);Group 2:receive a HFD;Group 3-5 receive HFD for 8 weeks followed by Indirubin-3'-monoxime treatment (0.1,0.2 and 0.4mg/kg i.p,respectively) once daily for 1 week.Indirubin-3'-monoxime is dissolved in (2.5% v/v) DMSO in saline. The mice in NPD and HFD groups receive an equivalent volume of vehicle (2.5% v/v DMSO in saline).Doses of Indirubin-3'-monoxime are selected.Mice are kept under standard husbandry conditions (22±1℃ and 60% humidity) and maintained on a 12/12-h light/dark schedule with free access to food and water for 8 weeks.Body weight is recorded weekly throughout the experimental period.

保存条件：

-20℃

UN码：

HazardClass：

危害声明：

安全说明：

点击下载核磁/氢谱图谱(PDF)

点击下载高效液相/气相图谱(PDF)

搜索质检报告(COA)

参考文献 & 客户发表文献